Calidi Biotherapeutics, Inc.
CLDINYSE
$0.12
↑ +2.9%Jul 17 close · end-of-day
Price
1Y↓ -98.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.2M
Enterprise Value
$1.8M
P/E
—
P/S
—
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$19.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-385.6%
ROIC
-276.4%
Debt / Equity
0.1
Net Cash
-$600,000.00
Return 1Y
-98.4%
Company profile
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. The company was founded in 2014 and is based in San Diego, California.
- CEO
- Allan J. Camaisa
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 38
- Headquarters
- California
- Website
- www.calidibio.com
Management & directors
- Jackson Andrew C.Chief Financial Officer
- Poma Eric EChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
CLDI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.43↓ -80.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $45,000.00 | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$23.1M | -$29.0M | -$21.8M | -$20.2M |
| Net income | -$25.4M | -$29.2M | -$22.1M | -$19.9M |
| Diluted EPS | $2.99 | -$17.33 | -$35.70 | -$5.95 |
| Operating cash flow | -$13.2M | -$27.0M | -$19.7M | -$21.3M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | -51395.6% | — | — | — |
| Net margin | -56504.4% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.8M | -$5.2M | -$4.0M | -$5.1M | -$5.7M | -$5.0M | -$4.5M | -$4.2M |
| Net income | -$5.8M | -$5.1M | -$4.1M | -$5.0M | -$5.7M | -$5.1M | -$4.1M | -$4.1M |
| Diluted EPS | -$16.75 | -$7.75 | -$9.17 | -$2.21 | -$1.99 | -$2.21 | $0.46 | -$0.43 |
| Operating cash flow | -$5.5M | -$4.9M | -$5.4M | -$7.1M | -$4.9M | -$4.2M | -$5.0M | -$4.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-12 | Camaisa Allan | Sale | 850 | $1.46 | $1,236.75 | filing |
| 2025-08-21 | Leftwich Scott | Buy | 125,000 | $2.00 | $250,000.00 | filing |
| 2025-08-21 | Schoeneck James A | Buy | 75,000 | $2.00 | $150,000.00 | filing |
| 2025-08-21 | Poma Eric E· Chief Executive Officer | Buy | 25,000 | $2.00 | $50,000.00 | filing |
| 2025-08-21 | Jackson Andrew C.· Chief Financial Officer | Buy | 2,500 | $2.00 | $5,000.00 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.